The U.S. Patent and Trademark Office recently released a second patent to a Florida based company, Myolite, for technology to use light therapy to reduce the progression of myopia (nearsightedness) in children. The patent, titled Electromagnetic Radiation Refractive Therapy, claims that the intracellular signal transduction networks that control eye growth can be modified by light sources of the appropriate color content and amount, direction and duration of light. At this point, while this is by no means a mature technology, I would consider this to be a promising vehicle for helping to control the development of nearsightedness in children in the future. This is of particular importance since the prevalence of nearsightedness in children is increasing worldwide. If a technology using just light, rather than chemical eye drop treatment, could help treat the development of nearsightedness, this could be of incredible importance. I look forward to following the progress of this exciting eye technology.